In this episode, we bring you an interview with Professor Elias Arnér from the Karolinska Institute. After a long international career in redox biology, Professor Arnér became CEO of Thioredoxin Systems, the company behind a potential new antibiotic with a novel target and mode of action: EbsArgent. We explore his background, the lessons he has learned, and what makes this new drug candidate so unique.

In the news section, Elin brings us a recent article on the resistance and potential collateral sensitivity of Ceftazidime-avibactam to treat P. aeruginosa strains. Eva shares the latest publication at our center, with PhD student Adrián Fernández López’s work on the mechanisms behind FusB-mediated resistance in Staphylococcus aureus.

We hope you enjoy this month’s episode, and see you on the next one!

Check relevant links in the show notes here. Follow our updates on ⁠twitter/X & Bluesky⁠ with #theAMRstudio hashtag! Theme music by ⁠Henrik Niss⁠.